this moment, all of our participants are connected only as listeners. Later, we will start the question-and-answer session when instructions for you to participate will be given.

Please remember that this audio conference is being recorded. I would like to now pass the microphone to Carlos Gil, CEO of the Oncoclínicas Group.

Carlos Gil, please go ahead.

Good

morning. Thank you for all of your presence.

I would like to compliment our investors, our analysts, and the other participants who are accompanying the release of the results of the first quarter of 2026. It was a quarter that was very challenging for the company, marked by strong operational pressure and financial pressure.

We confronted a complex scenario which demands of administration quick decision-making, and principally, responsibility in the conduction in the operations. Since the beginning, the priority has been clear: preserve the continuity, and maintain the sustainability of the company for the long term.

We have been through relevant impacts from the pressure from liquidity, with temporary effects about the certain operations, especially in the supply of medications. This theme was treated with the maximum priority and seriousness, and we operate in a active and coordinated way to establish operations and minimize the impacts on the assistance and accelerate the normalization of our services.

In this context, we started important initiatives to recompose the gradual supply of medications, and in partnership with Lumina and Oncoprod, which represents this in our operational restructuring plan. Our focus is on equalizing the treatments that have been held back, and recovering the operational efficiency and the gradual reconstruction of the company.

In spite of the challenges confronted in this quarter, I would like to emphasize that we have solid fundamentals and ethical fundamentals. Oncoclínicas maintains its leadership position in oncology in Brazil, with national presence and with a important strategic role in the area of oncology and health in the country.

I'd like to take advantage of this moment that we count on a clinical team which is committed. Movements at the entrance and coming back of this doctors, which is natural in our sector, and up until the moment, we have not seen any relevant impact on our operations or capacity to attend our patients.

We have a great deal of consciousness that we'd have to have rationality in allocation of capital. That's exactly what we're concentrated on right now.

The measures implemented in recent months have started to rebuild a more sustainable basis for the recovery of the growth with profitability and the strengthening of the reputation of the company. We affirm that in this process, this will not happen from night to day.

It will be conducted with total transparency and responsibility, maintaining the market informed about all of the relevant advances. I'd like to pass it over to our acting CFO, Isaac Quintino, who will detail the financial results from the first quarter of 2026.

Thank you, Gil. Good morning to everyone.

It's a pleasure to be with you all once again. Beginning with slide number 3, we can, on the graph on the left, we can observe that a an evolution, a slight a a reduction in the number of procedures in the quarter, and here which principally impacts due to the lack of certain medications in certain regions in Brazil, as Gil mentioned just just mentioned.

This impact of not of lack of supply was principally in the middle of March going forward, and the impact which we calculated was for about R$40 million of revenue in this period, which we calculate about 4,000 procedures in this first quarter. Normalizing that, we will have basically the same number of procedures in last quarter, with a important growth in the average ticket of the company.

Here, I would like to mention that two factors: one, we had an advance in the pass-through of CMED in this in this period, we had several negotiations that we started to see in the first quarter, and we also had an impact of what we've been working on in recent years of the cleaning of some contracts and some payers who, beyond having pressure on their working on our working capital, have average tickets that are lower than our average. We then started to see this effect in the first quarter, and the tendency that we see on the sta- on the stability of these numbers in coming quarters.

The graph on the right shows exactly the effect of the last 12 months, which was a a higher falloff which comprehends the effects, the complete effect of this cleansing that we've been mentioning of our basis, of our client base, which we've been talking about over the last 12 to 18 months. On the next slide, our gross revenue, we see the effect of this Even though we've had a falloff in the number of procedures, we had an effective and a good effect on the average ticket, and so we see a growth, a sequential growth of 1%, and year-on-year, we have the effect of this sanitation, of this cleansing of our base as I just mentioned.

On the slide number 5, we see the impact principally of the PCLD in this quar- in this quarter. We had a an adjustment, a bigger adjustment in PCLD, and we have certain to give you some clarity, as we have a history of approximately 3% of through PCLD, which is provisioned for in slide 6, a long history of 3% of PCLD, and this quarter, which is the first quarter of this year, we're getting close to 100% of our accounts to receive almost 100%, which means that there is no, we're not applying any adjustment, management adjustment, to to this PCLD number, the effect which you considered in the past, and in certain payers, which at certain points in time during the negotiations have done several adjustments, management adjustments, which is no longer done in this first quarter.

The tendency, naturally, is that in the next quarters, we will go back to the normality of approximately 3%, understanding that this 14.3% of PCLD in this quarter was a one-time effect which will happen only during this first quarter, fruit of this adhesion of 100% of the rule of the PCLD for the company. As a consequence of this higher level of PCLD in the first quarter, we had a net revenue falling significantly in relation to the last quarter.

On slide number 7, I'm going to mention about our gross margin, where we have two effects. The first, as that what I mentioned right now, which is the on the PCLD,

but

beyond that, we had to we do the because of this lack of supply in medications, we had certain moments we had to do purchases of medications from local distributors, and naturally, we don't have the same margins, the same commercial and discounts that we have in national agreements, nationwide agreements, due to that. We had pressure on our gross margin occurring in the quarter.

As we see here, the gross margin, excluding the effects of the PCLD, both in the fourth quarter as well as in the first quarter, normalizing the PCLD at 3%, we go from 32.3% to 27.7%, and we understand that this fall is the fruit, specifically for the fruit of this question of the lack of supplies of certain medications and local purchases from local suppliers of these medications. Slide 8 is a good 8 as the beginning of the process of reduction of operating expenses.

As we've been mentioning, the company, since the beginning of the year, has been working on a zero budget for certain renegotiations of contracts with suppliers of of expenses, of IT contracts, contracts with suppliers, corporate suppliers, and this brought to the company in this first quarter a reduction, an important reduction, which should continue to appear in the next quarter in the coming quarters. Here we're going to leave here, make it more evident in the next weeks and months, what are the the principal initiatives in the in the zero-based budget on which we've been working to maintain the company, to bring it to the right size for the current moment of the company.

That's what the the financial plan here that we've been working on and add and making more adequate for the company. Also important to mention that in this quarter, we had a very low had we had a provision due to the risk of Unimed Fluminense, where we have a debt with they have a debt with us, and there were several failures in receipts of that payment for that on that debt, and so we made a provision for the total amount of that of that balance.

We continue to try to collect it, and we'll continue our efforts to negotiate. However, due to a higher level of being conservative on the part of our administration, due to the accounting and financial point of view, we opted to provision 100% of that of that balance, and this balance will then re- be counted as an expense in this quarter.

We adjusted this effect in the slides so that it becomes so that the expenses that we comp- the comparative expenses would be comparable on a recurring basis. Having said that, we had a reduction in the percentage of expenses on on revenue, which is important, which is that which we continue to see in coming quarters.

On slide number 9, our EBITDA, the same thing happened as I mentioned for the gross margin, appears also in the EBITDA margin as well. The effect of the PCLD, higher losses in this and which is reflected in our EBITDA margin, we put here the effect excluding or normalizing the PCLD both in the fourth quarter as well as in this quarter, we go from 11.2% margin in the quarter to 4 to 8.7% in this quarter, and with the effect basically due that which I mentioned about the purchase of medications from local suppliers.

Slide 10, the effect of the on of the loss, accumulated losses of this quarter, the effect which is not just of the of the non-payments, as well as a high level of leverage of the company, the company has no growth year on year. We have had a deleverage an operational deleveraging in this quarter, and beyond that, the sum of the interest in the period to get added to that with the accounting effect of the PCLD.

On slide number 11, working capital of the company, we continue and we continue to observe a a stability in the accounts receivable since the first quarter of last year. In the second quarter of last year was already a little bit better, and since then there has been a stability in this line of accounts receivable.

Here I would like to mention once again the strong work which is doing the company is doing on the cleaning of our of our client base so that this line will not vary as it has in the past. Beyond that, you will you will note the stabilization in the level of inventories.

This line of inventories here, as you can see, as you know very well in the past, was close to 10 days, and last year got to a maximum of 20 days of inventory, which is now down to 13 days.

The

the tendency is with the exit of the hospitals that we go back to our historic levels. Here the accounts payable, as we have renegotiated several balances that we had they were owned by our principal suppliers of medication, and this will continue to impact the days of accounts payable for some time.

We will be communicating this to the market as we advance in our formal negotiations, definitive with negotiations with our principal suppliers. Slide 12, the reconciliation of the of the cash on hand: we started the year with R$518 million cash on hand.

Our operation had negative operational cash flow. We did the anticipation of receivables of approximately R$330 million in the fourth quarter of last year, naturally these receivables were allocated for the first quarter, and so we had an important effect here on the cash operational cash flow due to this anticipation of receivables from the fourth fourth quarter, and so the payment of interest in January and February before the standstill period of R$65 million, and also a payment on the principal on the debt of approximately R$1,187 million, and also a period of pre- prior to the standstill period, the capex of approximately R$28 million in this quarter, a value which is much lower than the amount that we had been practicing in the past, and is also a line which should should should reach to even lower levels in the future, and also the payments of R$66 million for acquisitions and partnerships prior to the standstill period.

We also finalized the cash flow at this period in this period with R$124 million, which naturally this fact, together with a lower EBITDA in this quarter on slide 3, increases our leveraging from 3.5 time times net debt to EBITDA to 5.2 net debt to EBITDA. To give you an update, we have continued in our negotiation with our creditors, and shortly we should have we'll be able to re- release the advances in these negotiations.

We're continuing we continue optimistic in the negotiations on which we're working, and we will continue, as Gil mentioned, open to for any esclareci- for any clarifications and to give any details that we can to the market and for the financial markets. With that, I will wrap up my final my presentation, and we're open for any questions and answers.

Please raise your hand if you have any questions. Ladies and gentlemen, we now begin the question-and-answer session.

To make a question, please raise your hand through the button which is available in the videoconference, on the raise hand button. Reminding, ladies and gentlemen, that we will begin the question-and-answer session.

To make a question, please raise your hand through the available button in the videoconference. Thank you.

Since there are no questions, I will now return the microphone to Carlos Gil for his final comments. Dr.

Carlos, please go ahead. I'd like to thank you all for joining us today, and thank you very much in the name of Oncoclínicas Group.

Thank you very much. Thank you.

The conference of Oncoclínicas is now closed. We thank you for the participation of everyone.

Please have a good day.